Scientists Engineer Probiotic Bacteria to Target Pancreatic Tumors

Microbes as On‑Site Drug Factories

A team at the University of Chicago Medical Center has modified harmless gut bacteria to act as miniature factories that produce anti‑cancer molecules directly inside pancreatic tumors. In pre‑clinical trials, the engineered microbes entered tumor tissue, activated immune cells, and slowed tumor growth in mice.

The researchers began by selecting a common probiotic strain, Lactobacillus reuteri , known for its safety in humans. Using CRISPR‑based gene editing, they inserted a gene that encodes a protein capable of stimulating cytotoxic T cells. When the bacteria were injected into the bloodstream of mice bearing human pancreatic tumors, they migrated to the tumor site, released the protein, and triggered a robust immune response that reduced tumor size by up to 40 percent compared with controls.

The concept relies on the bacteria’s natural ability to colonize hypoxic tumor cores, where conventional drugs often fail to reach. By equipping the microbes with a tumor‑specific promoter, the scientists ensured that the anti‑cancer protein is produced only inside the tumor microenvironment, minimizing systemic exposure. „We essentially turned the bacteria into a delivery vehicle that can bypass the barriers that limit chemotherapy,” explained Dr. Maya Patel, the study’s senior author.

How Far Is the Road to Human Trials?

In addition to protein production, the engineered strain was engineered to secrete a small molecule that reprograms tumor‑associated macrophages from a pro‑tumor to an anti‑tumor state. Flow‑cytometry analysis showed a 3‑fold increase in activated T cells within the tumor after treatment. The dual action—direct protein secretion and immune modulation—appears to be responsible for the observed tumor regression.

While the results are promising, several hurdles remain before the therapy can be tested in patients. First, the safety profile must be confirmed in larger animal models, as the engineered bacteria could potentially cause unintended inflammation. Second, the manufacturing process for clinical‑grade bacterial preparations needs to meet stringent regulatory standards. Finally, the researchers plan to test the therapy in combination with checkpoint inhibitors to evaluate synergistic effects.

Dr. Patel noted that the approach could be adapted to other solid tumors by swapping the promoter sequence to match different tumor markers. „The platform is modular,” she said. „Once we have a robust delivery system, we can tailor the therapeutic payload to the cancer type.”

The study, published in Nature Biotechnology , marks a significant step toward harnessing the microbiome for precision oncology. If successful in humans, this strategy could offer a new avenue for treating pancreatic cancer, a disease that has long resisted conventional therapies.

Frequently Asked Questions

What makes probiotic bacteria suitable for cancer therapy? Probiotics are naturally tolerated by the human body, can survive in the gut, and possess the ability to colonize tumor tissues, making them ideal carriers for therapeutic molecules.

Will the engineered bacteria remain in the body after treatment? The bacteria are designed to be cleared by the immune system after delivering their payload. However, long‑term studies are needed to confirm complete clearance.

Could this approach work for other cancers? Yes. By changing the genetic elements that control protein expression, the system can be adapted to target various tumor types beyond pancreatic cancer.